Literature DB >> 21923778

EUCAST technical note on anidulafungin.

M C Arendrup1, J-L Rodriguez-Tudela, C Lass-Flörl, M Cuenca-Estrella, J P Donnelly, W Hope.   

Abstract

The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing has determined breakpoints for anidulafungin for Candida spp. This Technical Note is based on the EUCAST anidulafungin rationale document (available at: http://www.eucast.org). Species-specific breakpoints for C. albicans are S ≤0.03 mg/L and R >0.03 mg/L and for C. glabrata, C. tropicalis and C. krusei S ≤0.06 mg/L and R >0.06 mg/L. C. parapsilosis was not regarded a good target for anidulafungin. There are insufficient data to set breakpoints for other species. The breakpoints are based upon pharmacokinetic data, epidemiological cut-off values and clinical experience. Breakpoints will be reviewed regularly.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21923778     DOI: 10.1111/j.1469-0691.2011.03647.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  28 in total

1.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

2.  Favorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin.

Authors:  Jop Jans; Roger J M Brüggemann; V Christmann; Paul E Verweij; Adilia Warris
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

3.  Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.

Authors:  Rasmus Hare Jensen; Helle Krogh Johansen; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

Review 4.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

5.  Outbreak of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan in 2011.

Authors:  Chun-Ming Lee; Chun-Hsing Liao; Wen-Sen Lee; Yung-Ching Liu; Jung-Jung Mu; Meng-Chih Lee; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

6.  Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Richard Cumbie; Eileen Driscoll; A William Pasculle; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

7.  Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin.

Authors:  María Teresa Durán-Valle; Sara Gago; Alicia Gómez-López; Manuel Cuenca-Estrella; Leticia Jiménez Díez-Canseco; José Luis Gómez-Garcés; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

8.  Limited-sampling strategies for anidulafungin in critically ill patients.

Authors:  Marjolijn J P van Wanrooy; Johannes H Proost; Michael G G Rodgers; Jan G Zijlstra; Donald R A Uges; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

9.  Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.

Authors:  A Forastiero; V Garcia-Gil; O Rivero-Menendez; R Garcia-Rubio; M C Monteiro; A Alastruey-Izquierdo; R Jordan; I Agorio; E Mellado
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

10.  Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications.

Authors:  A Forastiero; A C Mesa-Arango; A Alastruey-Izquierdo; L Alcazar-Fuoli; L Bernal-Martinez; T Pelaez; J F Lopez; J O Grimalt; A Gomez-Lopez; I Cuesta; O Zaragoza; E Mellado
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.